Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/24/2026 04:24 PDT] CAPS Expected to Trade Up After Bullish Patterns Develop
• [04/21/2026 09:28 PDT] CAPS Expected to Trade Down After Bearish Patterns Develop
• [04/16/2026 10:30 PDT] Capstone Holding Corp. (OTC:CAPS), Up By 100% ($0.54) From $0.541 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/09/2026 06:59 PDT] CAPS Expected to Trade Up After Bullish Patterns Develop